Agennix Halves Headcount, Closes Houston Site, Following Talactoferrin Failure In NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.
You may also be interested in...
Wealthy Families Play A Growing Role in European Biotech Financing
The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.
Financings Of The Fortnight: Finding Comedy In Today's Financial Environment
A Magic 8-Ball assesses the Sanofi/Genzyme intrigue, while Convergence, Agennix, Tobira and CtyomX highlight a busy two weeks in biotech finance.
Novartis And Antisoma's ASA404 Stumbles Badly In A Phase III Lung Cancer Trial
Prospects for what was thought to be a promising first-in-class lung cancer treatment dim after a Phase III trial is halted early due to futility of improving survival.